Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.36 |
| ▸ | DDR2 | Q16832 | 7/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643666 | 0.92 | PDE2A (0.39) | RORCPDE2ADDR2NR1I2CYP2C9 | |
| SCHEMBL1643203 | 0.91 | LMNA (0.41) | RORCDDR2NR1I2CYP2C9CA2 | |
| SCHEMBL1285387 | 0.87 | TRPV1 (0.39) | RORCPDE2ANR1I2CYP2C9CA2 | |
| SCHEMBL1643883 | 0.86 | PDE2A (0.33) | RORCPDE2ANR1I2CYP2C9MEN1 | |
| SCHEMBL1644603 | 0.83 | MEN1 (0.37) | PDE2ALMNAALDH1A1MEN1KMT2A | |
| SCHEMBL1643659 | 0.81 | LMNA (0.40) | LMNAALDH1A1 | |
| SCHEMBL1645545 | 0.80 | PDE2A (0.42) | RORCPDE2ADDR2LMNAALDH1A1 | |
| SCHEMBL1644338 | 0.79 | NR1H4 (0.48) | PDE2ALMNAALDH1A1 | |
| SCHEMBL1644517 | 0.79 | PDE2A (0.37) | PDE2A | |
| SCHEMBL264324 | 0.78 | PDE2A (0.41) | PDE2AMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | RORC 2710/4885PDE2A 1116/4885DDR2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.